CN101491550B - Composite preparation of red rice extract and coenzyme Q10 and preparation method thereof - Google Patents
Composite preparation of red rice extract and coenzyme Q10 and preparation method thereof Download PDFInfo
- Publication number
- CN101491550B CN101491550B CN2008100101929A CN200810010192A CN101491550B CN 101491550 B CN101491550 B CN 101491550B CN 2008100101929 A CN2008100101929 A CN 2008100101929A CN 200810010192 A CN200810010192 A CN 200810010192A CN 101491550 B CN101491550 B CN 101491550B
- Authority
- CN
- China
- Prior art keywords
- preparation
- ubiquinone
- monas cuspurpureus
- cuspurpureus went
- coenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 72
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 70
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 title claims description 35
- 229940110767 coenzyme Q10 Drugs 0.000 title abstract description 14
- 240000007594 Oryza sativa Species 0.000 title description 2
- 235000007164 Oryza sativa Nutrition 0.000 title description 2
- 235000007189 Oryza longistaminata Nutrition 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940057059 monascus purpureus Drugs 0.000 claims abstract description 64
- 239000000126 substance Substances 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000012071 phase Substances 0.000 claims abstract description 17
- 239000008346 aqueous phase Substances 0.000 claims abstract description 11
- 238000001694 spray drying Methods 0.000 claims abstract description 8
- 244000113306 Monascus purpureus Species 0.000 claims description 62
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 62
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 53
- 229940035936 ubiquinone Drugs 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000003921 oil Substances 0.000 claims description 17
- 235000019198 oils Nutrition 0.000 claims description 17
- 238000010792 warming Methods 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 4
- 229960003964 deoxycholic acid Drugs 0.000 claims description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229960001947 tripalmitin Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000012138 yeast extract Substances 0.000 abstract 4
- 238000010008 shearing Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 125000005456 glyceride group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- 229930185723 monacolin Natural products 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- -1 coenzyme Q10 compound Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004833 fish glue Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000235349 Ascomycota Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229930186261 wentiquinone Natural products 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001326554 Elaphomycetaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000228427 Eurotiales Species 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241001314279 Zoopagales Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
Abstract
The invention provides a compound preparation of a red-yeast extract and coenzyme Q10 and a preparation method thereof, and relates to a compound preparation of the red-yeast extract and the coenzyme Q10 and the preparation method thereof for oral dosing, which are mainly used for preventing and treating cardiovascular diseases, and belong to the technical field of medicine and health-care products. The invention adopts the following technical proposal: ingredients of the compound preparation comprise the red-yeast extract and the coenzyme Q10, wherein weight portion of the red-yeast extract is between 5 and 30 portions; and weight portion of the coenzyme Q10 is between 1 and 5 portions. The preparation method comprises the following steps: taking each material according to the weight proportion; mixing the coenzyme Q10 with an oil phase substance; heating oil phase of mixture to a temperature of between 70 and 80 DEG C to dissolve the oil phase; placing the oil phase into aqueous phase to carry out high-speed shearing for 1 to 5 minutes; placing the oil phase in a high-pressure viscolizer to be circulated for 3 to 6 times at a pressure of between 30 and 100 megapascal; and carrying out spray drying to obtain the compound preparation.
Description
Technical field
The present invention relates to a kind of Monas cuspurpureus Went extract and ubiquinone of oral administration
10Compound preparation and preparation method thereof.Monas cuspurpureus Went extract of the present invention and ubiquinone
10Compound preparation is with Monas cuspurpureus Went medicinal substances extract and ubiquinone
10Be primary raw material, be prepared from, be mainly used in prevention, treatment cardiovascular disease, belong to medicine, health product technology field through certain preparation process.
Background technology
Monas cuspurpureus Went (Monas cuspurpureus Went) is Chinese Chinese medicine material and food, is mainly fermented by Monascus anka Nakazawa et sato.Monas cuspurpureus Went Pseudomonas mycota (Eumycophyta), Ascomycota (Ascomycota), Euascomycetes (Euascomycetes), diffusing ascus Zoopagales (Eurotiales), Monas cuspurpureus Went Cordycepps (Monascaceae), Monas cuspurpureus Went Pseudomonas (Monascus).Being inoculated in Monas cuspurpureus Went that rice fermentation obtains by Monascus anka Nakazawa et sato, to be applied to traditional food painted and as medicinal always.Put down in writing in Ming Dynasty's Compendium of Material Medica: " Monas cuspurpureus Went, warm in nature, sweet in the mouth help digestion and invigorate blood circulation, the dry stomach of spleen invigorating.Wine brewing, the capable medicine gesture of removing blood stasis." from Monas cuspurpureus Went fermentation liquid, find and separate to obtain significantly suppressing the synthetic active substance Monacolin of body inner cholesterol K (he is left alone without help) until Japan's rattan chapter far away; people begin to have given new extensive concern to natural Monas cuspurpureus Went and Monacolin compounds, and the Monacolin compounds has definite effect to blood lipid regulation and cholesterol reducing.Also there are a large amount of monascorubins and various active materials such as ergosterol, unsaturated fatty acid, polysaccharide, saponin, flavone and cellulose in the Monas cuspurpureus Went with antioxidation.A large amount of clinical pharmacologies studies confirm that Monas cuspurpureus Went has significant cholesterol reducing and blood fat at present.U.S. FDA in 1987 the official approval lovastatin (lovastatin, i.e. Monacolin K) be used for clinical.Up to now, the U.S. and Japan etc. have developed a series of statinses such as Lovastatin, Provastatin, Simvastatin and Atorvastatin etc., and its main component is Monacolin (he is left alone without help) compounds.There are Xuezhikang, zhibituo and heart health medicine etc. in China with the blood lipid-lowering medicine and the health food of Monas cuspurpureus Went exploitation.
Ubiquinone
10Have another name called ubiquinone, be also referred to as certain herbaceous plants with big flowers alkene quinone, ubiquinol, vitamin Q, vitamin ubiquinone, English name is Coenzyme Q
10, Ubiquinone, molecular formula is C
59H
90O
4This material be human body from the body material, also extensively be present in organs such as animal hearts, can from animal hearts, extract and obtain, also can be by chemosynthesis, biosynthesis obtains.Ubiquinone
10It is indispensable important physiologically substance in the human body, its chemical constitution characteristics have determined it to have many important physiological function in human body, it is a transmitter substance important in the vital movement, it is the key material of mitochondrial respiratory key rate-limiting reaction, generate at cellular energy, strengthen the biologos aspect and play a significant role.Contain Q in the human body
10Total amount is 500-1500mg, peaks about 20 years old, reduces rapidly then, and 70 years old reduces 57% than 20 years old youngster later on.Discover, in a lot of ill patients, ubiquinone
10Physiological level descends obviously, in the heart failure patient, and ubiquinone in patient's cardiac muscle and the blood
10Content obviously reduces, and replenishes ubiquinone from external source
10After, obviously improve patient symptom.Discover a lot of hypoimmunity patients, its ubiquinone
10Physiological level is lower, replenishes ubiquinone
10After, symptom improves.Modern medicine study finds that his left alone without help class medicine is the HMG-CoA reductase inhibitor, in the time of the performance drug effect, and blocking-up body coenzyme Q
10Biosynthesis, the patient takes his left alone without help class medicine for a long time can cause the body coenzyme Q
10Level reduces, and then causes many related side effects to take place, as hepatorenal damage and muscle damage.As document Ital J Biochem.1995, Jan-Feb; 44 (1): 1-9.Marinari UM, Pronzato MA, Dapino D, Gazzo P, Traverso N, Cottalasso D, Odetti P. and document Proc Natl Acad Sci USA.1990 Nov; 87 (22): 8931-4.Folkers K, Langsjoen P, Willis R, RichardsonP, Xia LJ, Ye CQ describes among the Tamagawa H..Therefore, human body replenishes ubiquinone from external source
10Treat various ubiquinones
10Physiological level lowly becomes a kind of feasible clinical treatment method.
Monas cuspurpureus Went and ubiquinone
10All belong to and derive from natural health substance, cardiovascular system is all had health care and therapeutical effect preferably, but physiological action stresses face and mechanism has certain difference, has complementarity, but be independent use substantially in the market.Monas cuspurpureus Went relies on that to contain natural HMG-CoA reductase inhibitor be his left alone without help class component for reducing blood fat and other antioxidant contents, hyperlipidemia and hypercholesterolemia are had strong pharmacological action, but because its main effective ingredient for his left alone without help compounds, will be blocked ubiquinone
10Biosynthesis, influence the body coenzyme Q
10Level, more existing documents have confirmed this point, as H.T.YangYang HT, Lin SH, Huang SY, Chou HJ. is at magazine Br J Nutr 2005; 93:131-135. in described Monas cuspurpureus Went and can reduce the multiple ubiquinone of organizing in the rat body
10Level is so the long-term Monas cuspurpureus Went extract that uses separately may produce certain side effect.In addition owing to ubiquinone among the patient crowd that cardiovascular disease is arranged
10Level is generally low, also needs additionally to replenish ubiquinone
10To normal level.
Summary of the invention
The present invention is exactly at the problems referred to above, provides a kind of and overcomes the side effect hidden danger that single clothes Monas cuspurpureus Went exists, and the Monas cuspurpureus Went and the ubiquinone of cooperative compensating effect are arranged
10Compound preparation and preparation method thereof.
For achieving the above object, the present invention adopts following technical scheme, and the present invention's batching comprises Monas cuspurpureus Went extract, ubiquinone
10, the parts by weight of Monas cuspurpureus Went extract are 5～30 parts, ubiquinone
10Parts by weight be 1～5 part.
Can also add adjuvant and prepare water dispersible stable compound preparation, prepare burden for the Monas cuspurpureus Went extract parts by weight be 5～30 parts, ubiquinone
10Parts by weight be that 1～5 part, the parts by weight of oil phase substance are 5～20 parts of 5～30 parts, the parts by weight of 10～60 parts of the parts by weight of aqueous phase substance, emulsifying agent.
Ubiquinone among the present invention
10Be liposoluble substance, be insoluble in water, relatively poor to light, heat stability, bioavailability is low.Monas cuspurpureus Went extract of the present invention has certain water solublity, and contains the Lip river and cut down his left alone without help and monascorubin, and the monascorubin that is contained is highly stable, has stronger interception, therefore both above-mentioned physicochemical properties be can utilize, microcapsule or nanoparticle are prepared into, fat-soluble ubiquinone with oil-in-water type
10Melt mutually separately or with liposoluble substance, as oil phase, soluble in water with Monas cuspurpureus Went extract and water-soluble substances, as water, under surfactant or emulsifying agent effect, carry out homogenizing and disperse, form nano dispersion fluid, after spray drying or the lyophilization, form water dispersible Monas cuspurpureus Went extract and ubiquinone
10Compound preparation.In this compound preparation, the monascorubin that contains in the Monas cuspurpureus Went extract contains ubiquinone with the common parcel of other adjunct ingredients
10Liposome has improved ubiquinone
10Stability and dissolubility, form and to contain Monas cuspurpureus Went extract and ubiquinone simultaneously
10Compound preparation, and have higher solubility, reached pleasantly surprised effect.
The preparation method of the Chinese medicine Monas cuspurpureus Went extract among the present invention is that employing Monas cuspurpureus Went material with present known technology, adds water or ethanol or methanol and extracts, and obtains after the drying.Mainly contain the Lip river in the Monas cuspurpureus Went extract and cut down compositions such as his left alone without help and monascorubin.Also can directly buy Monas cuspurpureus Went extract from the market.Ubiquinone
10Raw material adopts the commercially available product that meets standards of pharmacopoeia.
Oil phase substance can adopt vegetable oil, fatty glyceride in the adjuvant of the present invention, solid fatty acid any one or theys' mixture, vegetable oil can be any mixture of any one or they of soybean oil, olive oil, rapeseed oil, Petiolus Trachycarpi oil, Oleum Sesami, safflower oil, Semen Maydis oil, perilla oil, fatty glyceride can be monoglyceride, mountain Yu acid glyceride, Palmic acid glyceride, mixed acid glyceride, polyglycerol fatty acid fat is a kind of or their any mixture, and solid fatty acid can be a stearic acid, Palmic acid is a kind of or their mixture.Aqueous phase substance can adopt gelatin, fish glue, arabic gum, any one of sugar and sugar alcohols or their mixture, sugar can be a kind of of lactose, sucrose, mannose, trehalose, maltose or their any mixture, and sugar alcohol can be a kind of of mannitol, sorbitol, xylitol, maltose alcohol or their mixture.Emulsifying agent adopts non-ionic surfactant Tween 20,40,60,80, deoxycholic acid, any one of poloxamer, phospholipid, sucrose fat, fatty acid polyglycol glyceride or their any mixture.
The preparation method of compound preparation of the present invention is got various materials by above-mentioned weight fraction, gets ubiquinone
10, mixing with oil phase substance, heating is warming up to 70～80 ℃ with oil phase substance, makes dissolving; Water intaking phase raw material of substance and emulsifying agent are soluble in the aqueous phase in the material, and above-mentioned Monas cuspurpureus Went extract is dissolved in the aqueous phase substance, are warming up to 70～80 ℃; Oil phase substance is put into aqueous phase substance, carried out high speed shear 1～5 minute, put into high pressure homogenizer then, under 30～100 MPa pressure, circulate 3～6 times, spray drying obtains compound preparation of the present invention then.
The method of homogenizing can adopt the Ultrasonic Pulverization method to substitute, and spray drying can adopt freeze-drying to substitute.
Beneficial effect of the present invention:
The present invention has improved Monas cuspurpureus Went or ubiquinone
10The drug effect of using has been improved the ubiquinone that target of the present invention is used the crowd
10Low physiological level more helps preventing and treating cardiovascular disease, the side effect of having avoided the life-time service Monas cuspurpureus Went extract to cause, because two kinds of materials are formed compound preparation, the patient takes more convenient.Preparation of the present invention is easier dispersing or dissolving in water, ubiquinone
10More stable, and improved bioavailability.
The specific embodiment:
Below description by the specific embodiment the present invention is described in further detail; but this can not be used to limit protection scope of the present invention; those skilled in the art are according to basic thought of the present invention; can make various modifications or improvement; but only otherwise break away from basic thought of the present invention, all within the scope of the present invention.
Embodiment 1
Get ubiquinone
1010g, Monas cuspurpureus Went extract 300g, mix homogeneously.
Embodiment 2
Get ubiquinone
1050g, Monas cuspurpureus Went extract 300g, mix homogeneously.
Embodiment 3:
Get ubiquinone
1010g, soybean oil 25g, glyceryl monostearate 25g mixes, and heat temperature raising to 75 ℃ is standby.Get trehalose 100g, Monas cuspurpureus Went extract 50g, tween (80) 30g is dissolved in the 2000g water jointly, be warming up to 75 ℃, oil phase is joined in the aqueous phase substance, sheared 5 minutes, put into high pressure homogenizer then in the mulser high speed, under 100 MPa pressure, circulate 3 times, spray drying obtains compound preparation of the present invention then.
Emulsifying agent can adopt polysorbas20,40,60, phospholipid, poloxamer, deoxycholic acid to replace.Soybean oil can adopt Semen Maydis oil, olive oil, rapeseed oil, safflower oil, Petiolus Trachycarpi oil, perilla oil to replace.Glyceryl monostearate can adopt Glyceryl Behenate, tripalmitin, mixed acid glyceride to replace.Trehalose can adopt lactose, sucrose, maltose, mannose, mannitol, xylitol, gelatin, fish glue, arabic gum to replace.
Embodiment 4
Get ubiquinone
1010g, Palmic acid glyceride 150g mixes, and heat temperature raising to 75 ℃ is standby.Get lactose 200g, gelatin 100g, Monas cuspurpureus Went extract 300g, phosphatidase 15 0g, poloxamer (188) 100g, deoxycholic acid 50g, be dissolved in jointly in the 5000g water, be warming up to 75 ℃, oil phase substance is joined in the aqueous phase substance, sheared 5 minutes in the mulser high speed, put into high pressure homogenizer then, under 60 MPa pressure, circulate 3 times, spray drying obtains compound preparation of the present invention then.
Embodiment 5
Get ubiquinone
1050g, heat temperature raising to 75 ℃, standby.Get trehalose 300g, fish glue 300g, Monas cuspurpureus Went extract 300g, tween (20) 50g, poloxamer (188) 50g, be dissolved in jointly in the 5000g water, be warming up to 75 ℃, oil phase substance is joined in the aqueous phase substance, sheared 5 minutes in the mulser high speed, Ultrasonic Pulverization is 10 minutes then, and lyophilization then obtains compound preparation of the present invention.
Embodiment 6
Press the compound preparation raw material midbody of embodiment 3 preparations, be prepared into capsule, tablet, granule according to known technology.
Embodiment 7
The sample of embodiment 4 preparations and the sample of embodiment 1 preparation are got in the water dispersible test, and according to concentration 1mg/ml configuration solution, acetonideexample 4 samples can form homogeneous solution, ubiquinone in embodiment 1 sample
10Swim in the solution.
Embodiment 7
Stability test is got the sample and the ubiquinone of the preparation of embodiment 3 methods
10Raw material carries out illumination, high thermal stability test.
1, influence of light test
Get the raw material ubiquinone
10With Monas cuspurpureus Went extract mixture, ubiquinone
10Raw material, and preparation of the present invention placed 10 days under 4000LX light, respectively at 0 day, 5 days, 10 days sampling and measuring, the results are shown in Table 1.
Table 1 light is to ubiquinone
10Influence:
Table 1 shows that light is to ubiquinone
10Considerable influence is arranged, and preparation light stability wherein of the present invention is better than ubiquinone
10Raw material and mixture.
2, temperatures involved test
Get preparation of the present invention and mixture and raw material at 60 ℃, placed 10 days,, the results are shown in Table 2 respectively at 0 day, 5 days, 10 days sampling and measuring.
Table 2 high temperature is to ubiquinone
10Influence (60 ℃):
Table 2 shows that temperatures involved is less.
Embodiment 8
Transfer the blood fat experimental study, experimental technique: the feed high lipid food causes the hyperlipidemia rats model, model is subjected to the reagent thing after setting up, test the 14th day enzymatic assays rat blood serum T-CHOL (TC), serum triglycerides (TG), HDL-C (HPL), the content of low-density lipoprotein cholesterol (LDL).5 administration groups and a high fat matched group and a blank group are established in experiment, the administration group is respectively Monas cuspurpureus Went extract group (0.54g/kg wherein Lip river cut down his left alone without help content be 3.1%), Monas cuspurpureus Went coenzyme Q10 simple mixtures group (5.0g/kg, press embodiment 1 method preparation), the basic, normal, high dosage group of the water dispersible compound preparation of Monas cuspurpureus Went coenzyme Q10 (preparing) by embodiment 4 methods (dosage is respectively 5.0,2.5,0.5g/kg wherein high dose group contain the Lip river to cut down his left alone without help amount consistent with the Monas cuspurpureus Went extract group).The rat feeding normal feedstuff observed for 2 weeks under experimental situation, got blood, surveyed the normal value of TC observation index.Begin each treated animal from formal experiment and fed for 2 weeks, get blood, measure blood fat to determine whether to form hyperlipemia, after hyperlipidemia model is set up, again according to TC level, random packet with high lipid food.Every group 10, when continuing high fat and feed, each organizes equal gastric infusion, and every day 1 time, in continuous 2 weeks, every index is measured in blood sampling in the 14th day.Each treated animal is put to death, and the separating animal's heart is measured ubiquinone after pre-treatment
10Content.The results are shown in following table 3, by the table result as seen, there was no significant difference (P＞0.05) between TC, the TG of each group, HDL, LDL during on-test, when testing 14 days, each administration group can significantly reduce the triglyceride (TG) of hyperlipemia rat, T-CHOL (TC), low-density lipoprotein cholesterol (LDL) content, each is organized blood lipid reducing content effect and is the water dispersible compound recipe of Monas cuspurpureus Went coenzyme Q10＞simple compound capsule＞Monas cuspurpureus Went of Monas cuspurpureus Went coenzyme Q10 in proper order.Animal hearts organizes coenzyme Q10 content to compare with the blank group, and the Monas cuspurpureus Went extract group descends 18%, and the dosage group descends 2% in the water dispersible compound recipe of Monas cuspurpureus Went coenzyme Q10, and the water dispersible compound recipe high dose group of Monas cuspurpureus Went coenzyme Q10 does not descend.
Each administration group of table 3 to the influence of lipid metabolic disorder rat blood serum lipid content (N=10,
Mmol/L)
| Group | Dosage (g kg -1) | ? | Lipids contents | (mmol·L 1) |
| TC | TG | LDL-C HDL-C | ? | ? |
| The blank group | --- | 1.4±0.21 | 1.11±0.17 | 0.78±0.15 0.54±0.04 |
| Model control group | --- | 3.42±0.30 | 2.61±0.18 | 2.25±0.19 0.45±0.18 |
| Monas cuspurpureus Went extract | 0.54 | 2.48±0.25 * | 2.05±0.20 * | 1.61±0.19 * 0.41±0.12 |
| The Monas cuspurpureus Went ubiquinone 10The simple mixtures compound recipe | 5.0 | 2.38±0.26 * | 1.98±0.14 * | 1.56±0.20 * 0.43±0.08 |
| The Monas cuspurpureus Went ubiquinone 10Water dispersible compound recipe | 5.0 | 2.09±0.15 * | 1.68±0.16 * | 1.31±0.18 * 0.40±0.15 |
| 2.5 | 2.36±0.23 * | 2.01±0.11 * | 1.58±0.17 * 0.43±0.03 | ? |
| 0.5 | 3.26±0.36 | 2.65±0.15 | 2.38±0.11 0.42±0.04 | ? |
Annotate: each group compares *: P＜0.05 with model control group
Claims (2)
1. Monas cuspurpureus Went extract and ubiquinone
10The preparation method of compound preparation is characterized in that getting ubiquinone
1010g, soybean oil 25g, glyceryl monostearate 25g mixes, and heat temperature raising to 75 ℃ is standby; Get trehalose 100g, Monas cuspurpureus Went extract 50g, tween 30g is dissolved in the 2000g water jointly, be warming up to 75 ℃, oil phase substance is joined in the aqueous phase substance, sheared 5 minutes, put into high pressure homogenizer then in the mulser high speed, under 100 MPa pressure, circulate 3 times, then spray drying.
2. Monas cuspurpureus Went extract and ubiquinone
10The preparation method of compound preparation is characterized in that getting ubiquinone
1010g, tripalmitin 150g mixes, and heat temperature raising to 75 ℃ is standby; Get lactose 200g, gelatin 100g, Monas cuspurpureus Went extract 300g, phosphatidase 15 0g, poloxamer 100g, deoxycholic acid 50g, be dissolved in jointly in the 5000g water, be warming up to 75 ℃, oil phase substance is joined in the aqueous phase substance, sheared 5 minutes in the mulser high speed, put into high pressure homogenizer then, under 60 MPa pressure, circulate 3 times, then spray drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100101929A CN101491550B (en) | 2008-01-22 | 2008-01-22 | Composite preparation of red rice extract and coenzyme Q10 and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100101929A CN101491550B (en) | 2008-01-22 | 2008-01-22 | Composite preparation of red rice extract and coenzyme Q10 and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101491550A CN101491550A (en) | 2009-07-29 |
| CN101491550B true CN101491550B (en) | 2011-12-28 |
Family
ID=40922452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100101929A Expired - Fee Related CN101491550B (en) | 2008-01-22 | 2008-01-22 | Composite preparation of red rice extract and coenzyme Q10 and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101491550B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102388971A (en) * | 2011-11-14 | 2012-03-28 | 江苏星驰生物科技有限公司 | Compound bovine colostrums powder |
| CN103613494B (en) * | 2013-11-05 | 2016-02-03 | 广东医学院 | Take Monascus anka Nakazawa et sato filament as technique and the production method that raw material extracts ubiquinone 10 |
| IT201700115088A1 (en) * | 2017-10-12 | 2019-04-12 | Pharmanutrition R&D S R L | Powder composition containing fermented red rice with high oral bioavailability |
| CN116035210A (en) * | 2022-12-30 | 2023-05-02 | 广州白云山汉方现代药业有限公司 | Method for solving layering of content and application of method in preparation of plant sterol ester red yeast soft capsules |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929437A (en) * | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| EP0383432A1 (en) * | 1989-01-18 | 1990-08-22 | Merck & Co. Inc. | Coenzyme Q10 with HMG-COA reductase inhibitors |
| CN1778391A (en) * | 2005-03-07 | 2006-05-31 | 淮北市辉克药业有限公司 | Safety and high-efficient compound hypolipidemic medicine |
-
2008
- 2008-01-22 CN CN2008100101929A patent/CN101491550B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0383432A1 (en) * | 1989-01-18 | 1990-08-22 | Merck & Co. Inc. | Coenzyme Q10 with HMG-COA reductase inhibitors |
| US4929437A (en) * | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| CN1778391A (en) * | 2005-03-07 | 2006-05-31 | 淮北市辉克药业有限公司 | Safety and high-efficient compound hypolipidemic medicine |
Non-Patent Citations (7)
| Title |
|---|
| Hui-Ting Yang,et al.Acute administration of red yeast rice (Monascus purpureus) depletes tissuecoenzyme Q10 levels in ICR mice.《British Journal of Nutrition》.2005,(第93期),131–135. * |
| 国家药品监督管理局.血脂康胶囊.《卫生部颁药品标准(新药转正标准中药第十六册)》.1997,x16-11~12. * |
| 实施例1. |
| 张小茜，等.高效液相色谱法测血脂康胶囊及红曲中洛伐他汀的含量.《中国中药杂志》.1997,第22 卷(第4 期),222-224. * |
| 毕殿洲.四、乳剂的制备.《药剂学第四版》.人民卫生出版社,2003,224-225. * |
| 第2栏第4-8,13-28行 |
| 说明书第2栏第4-5段 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101491550A (en) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101022786B (en) | Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients | |
| US9259401B2 (en) | Water soluble composition comprising curcumin having enhanced bioavailability and process thereof | |
| CN102405046B (en) | Pharmaceutical composition presenting anti-inflammatory properties | |
| CN102764408B (en) | Dealcoholic preparation | |
| CN106619588B (en) | It is a kind of containing Co-Q10 from micro-emulsion type alimentation composition, Preparation method and use | |
| CN104323283B (en) | Contain alimentation composition of Co-Q10 and preparation method thereof and application | |
| CN101491550B (en) | Composite preparation of red rice extract and coenzyme Q10 and preparation method thereof | |
| CA3148455A1 (en) | Solubilizate with curcumin and optionally at least one other active substance | |
| CN102475696A (en) | Water-soluble lutein and preparation process thereof | |
| US20070042009A1 (en) | Topical composition for delivery of salicylates | |
| CN1857334B (en) | Glossy ganoderma spore oil emulsion for intravenous injection and its preparing method | |
| CN101057678B (en) | Composition containing natural plant extraction or monomer | |
| CN101474150B (en) | Stable alprostadil injection emulsion and preparation method thereof | |
| US20220193008A1 (en) | Bioaccessibile compositions of lipophilic compounds and process thereof | |
| CN103859395B (en) | A kind of ubiquinone of high-absorbility 10self-emulsifying drug delivery system and preparation method thereof and application | |
| CN101011373A (en) | Pharmaceutical composition containing L-carnitine and preparation method thereof | |
| CN100515389C (en) | Medicinal emulsion adapted for difficultly soluble medicine and method for preparing the same | |
| CN1846776B (en) | Injection of long-chain fat from zedoary oil and its preparation process | |
| CN106387352A (en) | Microcapsule animal immunoenhancer containing tea polyphenol and preparation method of immunoenhancer | |
| CN100998867A (en) | Anticancer Chinese medicine compound nanometer emulsion and its preparation method | |
| CN107648307B (en) | Composition, preparation method and application thereof | |
| CA2745579C (en) | Thick pine needle extract composition for capsulation | |
| CN101897929B (en) | Improved composition as well as preparation method and application thereof | |
| CN109602893A (en) | A kind of composition and its preparation improving hepatic injury and organism fatigue | |
| TW200946140A (en) | Stable-type Cucurbitacin medicinal liquid compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LIAONING WANJIA PHARMACEUTICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: SHENYANG HAOTIAN WANJIA PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150312 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110015 SHENYANG, LIAONING PROVINCE TO: 110000 SHENYANG, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150312 Address after: Fengle Shenhe District of Shenyang city in Liaoning province 110000 Street No. 88 Patentee after: Liaoning Wanjia Medical Technology Co., Ltd. Address before: 110015 Liaoning Province in Dongling District of Shenyang City fengle Street No. 88 Patentee before: Shenyang Haotian Wanjia Pharmaceutical Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111228 Termination date: 20180122 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |